πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10738124

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10738113

Anti-IL-2 antibodies and compositions and uses thereof

The Regents of the University of California Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10738126

Anti-GITR antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10738081

Peptide with anti-obesity and anti-diabetes activity and use thereof

CAREGEN CO., LTD. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10738112

Anti-human interleukin-17A monoclonal antibody

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10736976

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10729767

Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage

Bioverativ USA Inc. Β· Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10729768

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

TG Therapeutics, Inc. Β· Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10729651

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. Β· Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10730944

Anti-CD8 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10730949

Method of treating PVNS with anti-CSF1R antibodies

Five Prime Therapeutics, Inc. Β· Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10722594

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10723764

Anti-microbial peptides and methods of use thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10723777

Peptide having anti-obesity and anti-diabetes efficacy and use thereof

CAREGEN CO., LTD. Β· Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10723787

Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10711068

Anti-CD133 monoclonal antibodies and related compositions and methods

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10702525

Pyrimidine derivatives as anti-diabetic agents

UNITED ARAB EMIRATES UNIVERSITY Β· Granted Tue Jul 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10689392

Anti-cancer compounds targeting ral GTPases and methods of using the same

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10689456

Anti-CD70 chimeric antigen receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10683347

Treatment of cancer using anti-TGF-Ξ² and anti-PD-1 antibodies

The Regents of the University of California Β· Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10683354

Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10675245

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. Β· Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10676480

Anti-cancer compounds targeting Ral GTPases and methods of using the same

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10669337

Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of

CytomX Therapeutics, Inc. Β· Granted Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted